Every human life is precious and sacred, saving one is like the saving of the whole of humanity. (Al Quran 5:32/33)
Source: Boston Globe
By Victoria McGrane
Three Massachusetts hospitals have received approval to launch the first US clinical trial of a Japanese flu drug that could be used to treat COVID-19, according to a doctor involved in the effort.
The trial — which will take place at Massachusetts General Hospital, Brigham and Women’s Hospital, and UMass Memorial Medical Center in Worcester — was approved by the federal Food and Drug Administration Tuesday. The small, randomized trial of the antiviral drug favipiravir will look to study its effectiveness as a treatment for patients infected with the coronavirus, according to doctors involved in the study.
The Japanese government has touted the drug, known by the brand name Avigan, as a possible treatment for COVID-19 Medical authorities in China have called the drug “clearly effective” in treating coronavirus patients after conducting two clinical trials.
Chinese researchers carried out two clinical trials of favipiravir, reporting positive results, though Fujifilm Toyoma Chemical, the drug’s developer, has declined to comment on the Chinese claims. Some of the data out of China showed that patients who were given the medicine were virus-free more quickly than those who did not receive the drug, and X-rays showed lung improvement among more of those who took the drug, according to news reports.
Suggested reading by Zia H Shah MD, Chief Editor of the Muslim Times
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
The self isolation for 70 years and older may last up to 4 months
To see the daily new cases and deaths in the top eleven countries go to
“We project that roughly 56 percent of our population – 25.5 million people – will be infected with the virus over an eight week period,” Governor Newsom of California wrote on 3/19/2020.